Heron Therapeutics | HRTX - 税前利润

金融业

USD

USD 246.22M

现金及等价物

USD 26.12M

USD 11.12M

USD 228.98M

USD 90.52M

USD 149.65M

股息收益率

0

USD 38K

USD -3.88M

126

EPS每股收益

USD -0.02

股本和储备

USD 9.14M

USD 29.47M

债务利息支出

USD 600K

USD 433K

USD 140.64M

USD 69M

USD -2.95M

USD 40.55M

USD 38K

普通股股本

USD 188.31M

USD -2.95M

USD 40.59M

销售和管理费用

USD 23.74M

USD 54.57M

贸易债权人

USD 8.97M

应收帐款人

USD 89.59M

	税前利润	更改		日
ALKERMES	USD -61.93M		122.3M	2026-03
Alnylam Pharmaceuticals	USD 221.65M		60.52M	2026-03
Amarin	USD -852K		7.26M	2025-12
ANI Pharmaceuticals	USD 31.48M		18.04M	2025-12
Anika Therapeutics	USD 764K		3M	2025-12
Arrowhead Research	USD 28.27M		7.85M	2025-12
Eisai	JPY -7.94B		29.94B	2026-03
GlaxoSmithKline	GBP 2.14B		919M	2026-03
Heron Therapeutics	USD -2.95M		14.54M	2025-12
Insmed	USD -162.1M		164.84M	2026-03
Ligand Pharmaceuticals	USD 56.78M		84.36M	2025-12
Merck	USD 3.42B		3.32B	2025-12
Nektar Therapeutics	USD -34.7M		2.35M	2025-12
Neurocrine Biosciences	USD 246.8M		7.4M	2026-03
Omeros	USD -65.12M		21.27M	2024-06
Pacira	USD 571K		8.95M	2025-12
Regeneron Pharmaceuticals	USD 1.04B		719.6M	2025-12
Roche Holding	CHF 11.17B		6.38B	2026-06
Sangamo BioSciences	USD -36.05M		12.94M	2024-06
Ultragenyx Pharmaceutical	USD -184M		56M	2026-03
Veracyte	USD 29.97M		10.66M	2026-03
Vertex Pharmaceuticals	USD 1.25B		78.1M	2026-03